Deprenyl Research Ltd. has received Canadian marketingapproval for Eldepryl as a first-line treatment for Parkinson'sdisease, the company announced on Tuesday.
Eldepryl deprenyl had previously been approved in Canada foruse in combination with L-dopa in late-stage Parkinson'sdisease.
"Deprenyl blocks the brain enzyme responsible for inactivationof dopamine, the transmitter which modulates ourmovements," said Roger Mailhot, director of scientific affairs atthe Toronto-based company (NASDAQ:DEPLF). It's not known,however, if the drug's efficacy is related to that activity, hesaid.
Deprenyl estimates that 30,000 Canadian patients would beeligible for treatment. In 1991, Eldepryl sales were $11.6million.
The company's shares rose 50 cents to $11.63.
(c) 1997 American Health Consultants. All rights reserved.